Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia

NCT07491263 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory CD19-positive B-ALL

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: QH103 Cell Injection

Sponsor

Fujian Medical University